Helix BioPharma Corp. Announces Fiscal 2008 Results

About this update from Helix Biopharma Corp.

[{"type":"text","content":"\n\n\n\nAURORA, Ontario, Oct. 28 /CNW/ -- Helix BioPharma Corp. (TSX, FSE: "HBP")\ntoday announced financial results for the year ended July 31, 2008.\n\n\n\n\n\nDuring the 2008 fiscal year, the Company continued to make progress with\nits development initiatives for its lead drug candidates, L-DOS47 and Topical\nInterferon Alpha-2b. The following are selected highlights during the 2008\nfiscal year and subsequent to year-end.\n\n\n\n\nKEY HIGHLIGHTS\n\n-- DOS47/L-DOS47\n -- Signed an agreement with a fill/finish provider to perform vial\n packaging of L-DOS47 for clinical testing.\n -- Signed an agreement with a company specializing in lyophilization\n (freeze-drying) to develop the L-DOS47 vial packaging format\n -- Signed a second, more definitive agreement with our L-DOS47 active\n drug substance and bulk drug product manufacturer to further scale\n up the GMP production process in preparation for clinical testing.\n -- Awarded a second U.S. patent protecting the use of targeted\n DOS47-based therapeutics, such as L-DOS47, in combination\n therapeutic regimens with certain chemotherapeutic agents\n-- Topical Interferon Alpha-2b\n -- Received regulatory approval to open sites in Germany for the\n ongoing Phase II clinical trial in patients with ano-genital\nwarts.\n -- Conducted meetings with German regulators as a preliminary step\n towards filing a CTA for a planned, large, randomized,\n placebo-controlled, double-blind Phase III European clinical trial\n in patients with low-grade cervical lesions.\n -- Signed an agreement to further scale up the production of Topical\n Interferon Alpha-2b in anticipation of conducting the planned\n European Phase III clinical trial in patients with low-grade\n cervical lesions, as well as to support the planned parallel,\n confirmatory U.S. Phase IIb clinical trial for this indication.\n-- Financing\n -- Completed a private placement financing on December 19, 2007 for\n gross proceeds of $16,867,200.\n -- Completed a private placement financing on October 2, 2008 for\n gross proceeds of $11,424,000.\n-- Other\n -- Appointed W. Thomas Hodgson to the Board of Directors.\n -- Subsequent to the year-end, Lumera Corporation gave notice to its\n termination of the biochip sub-license agreement, to be effective\n December 19, 2008.\n\n\n\nFor fiscal 2008, the Company recorded a net los...

More updates from Helix Biopharma Corp.